Browse Category

Mergers & Acquisitions News 13 November 2025 - 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics Inc. (NASDAQ: RPTX) is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right (CVR) structure that could unlock additional upside over the coming decade. Repare Therapeutics+1 As of this afternoon’s session, RPTX is changing hands around the low‑$2 range, not far above the estimated US$1.82 per‑share cash consideration embedded in the deal, and up close to 30% versus pre‑announcement levels, reflecting a classic
Ashurst–Perkins Coie Merger Creates $2.7 Billion Transatlantic Megafirm in Big Law Shake-Up

Ashurst–Perkins Coie Merger Creates $2.7 Billion Transatlantic Megafirm in Big Law Shake-Up

LONDON / SEATTLE — November 17, 2025 — London-headquartered Ashurst and US firm Perkins Coie have agreed to merge in a landmark transatlantic deal that will create a top‑20 global law firm with around 3,000 lawyers and annual revenue of about $2.7 billion. Operating under the new brand Ashurst Perkins Coie, the combined outfit will span 52 offices in 23 countries, cementing its status as one of the largest law firms in the world. Reuters+2Legal Cheek+2 A New Top‑20 Global Law Firm The merger is formally being described as a “combination of equals”, uniting two long‑established firms with more than
17 November 2025
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted monopolization.” Here’s a full rundown of what matters today, 17 November 2025, for anyone following Metsera, MTSR, or the obesity‑drug arms race. 1. Where the Metsera–Pfizer Deal Stands Today Pfizer formally closed its acquisition of Metsera on November 13, 2025, after Metsera shareholders approved a sweetened offer that values the obesity biotech at up to $10 billion.Reuters+1 Key terms of
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far.Reuters+1 The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of cheaper biosimilar rivals.Yahoo Finance+1 Key points Inside Johnson & Johnson’s Halda Therapeutics takeover J&J said on Monday that it will acquire Halda Therapeutics for $3.05 billion in cash, adding a new set of precision oncology assets to its Innovative Medicine unit.Reuters+1
TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

PARIS — November 17, 2025. TotalEnergies has agreed to acquire a 50% stake in Energetický a průmyslový holding’s (EPH) flexible power generation platform in a €5.1 billion, all‑stock transaction. The deal creates a 50/50 joint venture spanning more than 14 gigawatts (GW) of gas‑fired, biomass and battery assets across Italy, the UK & Ireland, the Netherlands and France, with closing targeted for mid‑2026 pending approvals. EPH will be paid in newly issued TotalEnergies shares and become a meaningful shareholder in the French energy major. TotalEnergies.com+1 Key facts at a glance Why this deal matters For TotalEnergies, the acquisition accelerates a
WPP Share Price Today: London Stock Jumps on Takeover Talk as FTSE 100 Exit Looms (17 November 2025)

WPP Share Price Today: London Stock Jumps on Takeover Talk as FTSE 100 Exit Looms (17 November 2025)

WPP’s London-listed shares staged a sharp rebound on Monday, 17 November 2025, as fresh takeover speculation and recent insider share buying tempted bargain hunters back into one of the UK market’s hardest‑hit blue chips. According to closing data from Hargreaves Lansdown, WPP plc (LON: WPP) ended the session at around 298p, up roughly 3.4% on the day, after trading between about 293p and 308p. That move adds to early‑morning gains that saw the stock jump more than 5% at one stage. Hargreaves Lansdown+1 Yet even after today’s bounce, the advertising group remains a shadow of its former self, with the share price down around 64% over
Warner Bros Discovery Stock Skyrockets on $60B Takeover Rumors

Warner Bros. Discovery (WBD) Stock Climbs as Paramount, Comcast and Netflix Line Up Bids in High‑Stakes Auction – November 14, 2025

Warner Bros. Discovery, Inc. (NASDAQ: WBD) moved back into the spotlight on Friday, November 14, 2025, as a potential sale of all or part of the media giant appeared to crystallize into a three‑way contest between Paramount Skydance, Comcast and Netflix. The growing prospect of a bidding war sent WBD shares higher and intensified scrutiny of the company’s strategy, leadership and balance sheet. TradingView+3Sports Business Journal+3The Wall Street Journal+3 At the same time, new regulatory and governance angles emerged: a prominent U.S. lawmaker raised antitrust concerns about a possible Netflix deal, and Warner Bros. Discovery quietly rewrote CEO David Zaslav’s
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is at the center of Wall Street’s attention today after Merck & Co., Inc. (NYSE: MRK) agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares more than 100% higher in a single session. Reuters+1 Below is a detailed look at today’s news (14 November 2025), the science behind Cidara’s lead flu-prevention asset CD388, the stock market reaction, and the wave of shareholder-law-firm investigations that emerged within hours of the announcement. Merck to Acquire Cidara for $221.50 Per Share in Cash Merck and Cidara announced this
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date: November 14, 2025Ticker: MTSR (Metsera, Inc.) – now being delisted On Friday, November 14, 2025, Metsera, Inc. officially disappears from the Nasdaq tape. Trading in Metsera (NASDAQ: MTSR) has been suspended after Pfizer completed its acquisition of the obesity-focused biotech in a deal valued at up to $10 billion, capping one of the fiercest pharma bidding wars of the year.
Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor, Inc. (NASDAQ: TRIP) returned to investors’ good graces on Friday after Mizuho upgraded the online travel company and lifted its price target, signaling Wall Street is starting to warm to an aggressive restructuring that includes layoffs, a Viator merger and a deeper bet on AI-powered travel experiences. Investing.com+1 As of mid‑day Friday, Tripadvisor shares were trading around $15.00, up roughly 1.5% from Thursday’s close at $14.78, though still well below their 52‑week high of $20.16. Investing.com+1 The bounce follows a bruising 6.75% slide on Thursday, when the stock sold off with the broader market despite recently reporting better‑than‑expected Q3
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck & Co. (NYSE: MRK) has agreed to acquire Cidara Therapeutics (Nasdaq: CDTX) in a deal valued at about $9.2 billion, a blockbuster move that gives the pharma giant a late‑stage, long‑acting influenza prevention drug as it prepares for life after cancer juggernaut Keytruda. Reuters+1 Key points at a glance Deal terms: a rich premium for a single late‑stage asset Under the definitive agreement announced this morning, Merck will, through a subsidiary, launch a tender offer to purchase all outstanding shares of Cidara for $221.50 per share in cash. That price represents a 108.9% premium to Cidara’s last closing price
Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air Corporation (NYSE: SEE), maker of Bubble Wrap, jumped to a 52‑week high on November 13, 2025, as private‑equity firm Clayton Dubilier & Rice reportedly explores a take‑private deal. Here’s what’s driving SEE stock today, including fresh buyout rumors, Q3 2025 earnings, analyst targets, and key risks. Sealed Air Corporation (NYSE: SEE) is suddenly one of Wall Street’s hottest tickers. The packaging company behind Bubble Wrap and Cryovac is rallying sharply today after multiple reports that private‑equity giant Clayton, Dubilier & Rice (CD&R) is exploring a takeover that could take Sealed Air private. By late morning on Thursday, SEE
1 21 22 23 24 25 34

Stock Market Today

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

Rio Tinto stock jumps as Glencore mega-merger is shelved; what to watch next week

7 February 2026
Rio Tinto’s U.S. shares closed up 2.5% at $93.37 Friday after the company ruled out a merger with Glencore, triggering a six-month “no-bid” lockout under UK takeover rules. Both companies cited disagreements over valuation. Attention now turns to Rio’s Feb. 19 results and iron ore prices, which fell below $100 a tonne amid weak Chinese demand.
iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Go toTop